Thomas Ferguson

机构：Fiona Stanley Hospital

发表论文 28 篇 · 总被引 1984 次 · h-index 11

代表论文

• Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma (2021 · New England Journal of Medicine · 被引 766)
• Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2022 · The Lancet Oncology · 被引 285)
• Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial (2023 · The Lancet Oncology · 被引 153)
• Taxanes for adjuvant treatment of early breast cancer (2019 · Cochrane Database of Systematic Reviews · 被引 89)
• Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer (2012 · British Journal of Cancer · 被引 67)
• Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC). (2024 · Journal of Clinical Oncology · 被引 35)